linjc16/ctgov huggingface dataset:
Cardiac Resynchronization Therapy (CRT)-Narrow-dp/Dt-Study

Study Overview
=================
Brief Summary
-----------------
Goal is to examine the efficy of Cardiac Resynchronization Therapy in heart failure patients with narrow QRS complex and optimized medical treatment but echocardiographic desynchronization detection as well as the positve increase of the intraoperative pressureincreasespeed in reverse remodelling and a secondary improvement of functional parameters

Official Title
-----------------
CRT in Patients With Narrow QRS, Echodesynchronisation and LV dp/Dt-Response With Pressure Wire

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Procedure: LV dp/dt pressure measurement
* Procedure: LV dp/dt pressure measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: EF < 35% CHD or dilate cardiomyopathy sinus rhythm NYHA III (or IV but stable recompenstated) QRS < 120 ms 2-3 of the following: LV-fillingtime < 40% of the cyclelength TDI septal-lateral (LV basal) > 60ms 2D-Strain-Score > 9 points Exclusion Criteria: tricuspid or artificial valve AV block II or III or PQ time > 250ms revasculisation or condition after cardiac surgery < 3 months myocardial infarction or bypass OP < 3 months hytertrphic obstructive cardiomyopathy, constrictive pericarditis intravenous catecholamines because of HF manifeste hyperthyreoses kidney failure (creatine >2,5 mg/dl) no written informed consent no compliance participation in another study life expectancy < 1 year patients < 18 years pragnancy or no safe contraception

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: CRT-ICD<br> | Procedure: LV dp/dt pressure measurement<br>* Assessment of response to bi-ventricular pacing. Responder-arm, will be permanently paced bi-ventricularly<br>|
| Placebo Comparator: DDD-ICD<br> | Procedure: LV dp/dt pressure measurement<br>* Assessment of response to bi-ventricular pacing. Non-esponder-arm, will be treated with standard ICD-treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Indexed left ventricular volume |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NYHA-class, 6 minute hallwalk, QOL, BNP-level, echo-criteria |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Narrow QRS, CRT
The Evaluation With Artificial Neural Network of Pain Scales in Children (ANN)

Study Overview
=================
Brief Summary
-----------------
The study evaluates with Artificial Neural Network (ANN) of pain scales in children. Pain of these patients' will be evaluated by many pain scales in the postoperative period.

Detailed Description
-----------------
Pain of these patients' will be evaluated by many pain scales in the postoperative period. These scales include OUCHER, Visiuel Analog Scale, FLACC, Faces Pain Scale revise, Wong Baker Faces Scale, Faces Pain Scale, Numeric rating Scale, Verbal Rating Scale, CHEOPS and also age, blood pressure, respiratuar rate, heart rate will be recorded. In the first step of this study, the parameters taken into account on widely used each pain scale practically and importance level of each parameter will be examined. The parameters taken into account in determining the degree of pain and degree of each pain scale will be recorded. Independent t-test of the pain scales will be analyzed whether different statistically. Pain scales used in the application at conclusion statistical analysis will be grouped. In addition, parameters considered to be effective on pain (pulse, blood pressure, etc.) will be determined and also recorded. The degree of importance on pain of the current scales and other parameters to be determined and as result, new pain scale will be created. While determining the the level of importance will be utilized from the analytic hierarchy process (AHP). Making binary comparisons between AHP and parameters, the level of importance and weightiness score of each parameter will be determined. The mathematical formulation of the pain points will be presented considering AHP weightiness score of each parameter. Although pain scores obtained mathematically, pain score with Artificial Neural Network (ANN) will be estimated considering the parameters that impact on the pain score. The final step, the creation of new pain scale comparing the pain scores obtained by mathematical formulation and Artificial Neural Network and, it is intended to be compared with the current scales.

Official Title
-----------------
The Evaluation With Artificial Neural Network of Pain Scales in Children

Conditions
-----------------
Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 2 months -18 years Children undergoing elective surgery Exclusion Criteria: Children with mental and motor development retardation Patients scheduled emergency surgery Patients and parents, who refused to participate in this study

Ages Eligible for Study
-----------------
Minimum Age: 2 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Artificial Neural Network | the creation of new pain scale | 4 months |
Influence of Tumor Associated Immunity on the Number of Lymph Node Retrieved After Colorectal Cancer Surgery (Preliminary Study)

Study Overview
=================
Brief Summary
-----------------
Hypothesis of this study is that increased immunity of primary tumor affects the increased number of lymph node retrieved. This study investigates whether immunity-related cytokine expression on primary tumor, colonic mucosa, and serum is associated with the number of lymph node retrieved in colorectal cancer patients.

Conditions
-----------------
Colorectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Histologically confirmed colorectal cancer 2. Non-metastatic cancer (cTNM I, II, or III) 3. Over 20 years of age 4. Curative resection (R0) Exclusion Criteria: 1. Patient with distant metastasis 2. History of chemotherapy or radiation therapy for malignancy 3. Patient receiving immunosuppressive or anti-inflammatory treatment 4. Hereditory colorectal cancer 5. Preoperative chemoradiation therapy for colorectal cancer 6. Pregnancy 7. Emergency

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Colorectal cancer patients<br>Colorectal cancer patients undergoing elective colorectal resection | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association between immune related cytokine and number of lymph nodes retrieved. | Immunity related cytokine - IL-12, IFN-r, GM-CSF, IL-4, TNF-a, IL-6, IL-8, IL-10, TGF-b1, CXCR4, SDF1, HGF, VEGF - expression is assessed using Bioplex assay. Patient serum is taken one day before surgery. Primary tumor and colonic mucosal tissue are taken just after surgery. Bioplex assay is performed after patients' enrollment | 2 months after surgery |
Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the safety and efficacy of priming vaccinations, and subsequent boosting vaccinations with Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®). Clinical observations and laboratory measurements will be monitored to evaluate safety and toxicity. Additionally, the antitumor effects of Allogeneic Prostate GVAX® on serum PSA levels will be evaluated and antitumor responses will be quantitated.

Official Title
-----------------
Phase I/II Study of a Prime-Boost Schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®) in Hormone-naïve Prostate Cancer Patients

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Biological: Immunotherapy allogeneic GM-CSF secreting cellular vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of adenocarcinoma prostate cancer No evidence of measurable metastatic disease An ECOG performance status of 0 or 1 Exclusion Criteria: Previous hormonal therapy of any type for prostate cancer Any previous chemotherapy, or prior investigational therapy for prostate cancer Prior Immunotherapy Prior treatment with gene therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Immunotherapy allogeneic GM-CSF secreting cellular vaccine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostate, Cancer, GVAX, Metastatic, Vaccine, Allogeneic cells
Clinical Study Evaluating the Efficacy and Safety of CID v2.2 in Glaucoma Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and effectiveness of implanting a new version of an interposition supraciliary implant (SV22) as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open and narrow angle glaucoma who have failed at least one class of topical medical therapy

Detailed Description
-----------------
35 patients will be included in this 36 months interventional study. All patients shall be indicated for glaucoma surgery alone (not combined with cataract), and will undergo incisional glaucoma therapy, including a simplified surgical technique allowing the placement of an interposition supraciliary permanent device. Several patient data like safety events, IOP, visual capacity or associated pharmacological treatments will be recorded pre and post-operatively all along the follow-up. Purpose is to ensure device safety, and verify IOP and associated pharmacological treatment reduction after surgery, and evolution along follow-up.

Official Title
-----------------
Multicentre, Non-randomised Clinical Study Evaluating the Efficacy and Safety of Cilioscleral Interposition Device v2.2 in Glaucoma Surgery

Conditions
-----------------
Glaucoma, Open-Angle, Glaucoma, Narrow Angle

Intervention / Treatment
-----------------
* Device: Cilioscleral Interposition Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of POAG Schafer 1 to 4 Medicated IOP ≥ 21 naive of any prior glaucoma surgery Exclusion Criteria: Inflammatory, congenital, traumatic, neovascular, ICE syndrome, angle closure and Schaffer 1 and 2 glaucoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cilioscleral Interposition Device<br>Any patients corresponding to inclusion / exclusion criteria | Device: Cilioscleral Interposition Device<br>* Surgical placement of SV22 cilioscleral interposition device in the supraciliary space<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess post-op IOP reduction | Proportion of eyes with >= 20% decrease in mean-Diurnal-IOP from baseline | 6 months |
Right Ventricular Function in Patients With Obstructive Sleep Apnea

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether patients with obstructive sleep apnea have any changes in right ventricular function evaluated by three dimensional echocardiography.

Detailed Description
-----------------
Several studies have reported the association between sleep disorders to an increased risk to the development of cardiac disease. However, there is no substantial that about the influence of Obstructive Sleep Apnea on the right ventricular function. Objective: to analyse the right ventricular function in patients with Obstructive Sleep Apnea by means of Real-Time Three dimensional Echocardiography.

Official Title
-----------------
Right Ventricular Function in Patients With Obstructive Sleep Apnea Assessed by Real-time Three-dimensional Echocardiography

Conditions
-----------------
Obstructive Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals > 18 years old and < 70. Exclusion Criteria: Body mass index greater than 35 Past of clinically significant cardiac conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1 - Obstructive Sleep Apnea (OSA)<br>Fifty-six patients with Obstructive Sleep Apnea | |
| Group 2 - Non-OSA Controls<br>Fifty individuals without OSA with similar age, gender and body mass index (BMI) | |
| Group 3 - Treatment<br>Fifteen patients with moderate and severe sleep apnea from group 1 underwent treatment with continuous positive airway pressure | |
| Group 4 - Placebo<br>Fifteen patients with moderate/severe sleep apnea underwent to placebo | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obstructive Sleep Apnea, Right Ventricular Function, Pulmonary Hypertension
Short and Long-term Results of Arterial Stiffness and Central Aortic Pressure After Kidney Transplantation

Study Overview
=================
Brief Summary
-----------------
Central blood pressure and pulse wave velocity were measured using a Complior Analyse device in Short and Long-term after kidney transplantation.

Official Title
-----------------
Short and Long-term Results of Arterial Stiffness and Central Aortic Pressure After Kidney Transplantation

Conditions
-----------------
Arterial Calcification, Aortic Stiffness, High Blood Pressure (& [Essential Hypertension])

Intervention / Treatment
-----------------
* Device: Device: Complior Analyse System
* Device: Tanita BC 418- Bioelectrical impedance analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: give voluntary consent to participate in the study functioning graft longer than 3 months to 10 years no clinical cardiovascular disease during the 6 months preceding entry stable graft function- glomerular filtration rate > 30 ml/min/1.73 m2, creatinine concentration <2.5 mg/dl medical staff (medical doctors, nurses) Exclusion Criteria: not meet the above criteria episode of illness (for example: infection) pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients after kidney transplantation<br>Short and Long-term results containing first 10 years after KTx. | Device: Device: Complior Analyse System<br>* Monitoring of Arterial Stiffness and Central Aortic Pressure<br>Device: Tanita BC 418- Bioelectrical impedance analysis<br>* The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).<br>|
| Healthy subjects<br>Medical staff: medical doctors, nurses | Device: Device: Complior Analyse System<br>* Monitoring of Arterial Stiffness and Central Aortic Pressure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences in carotid-femoral pulse wave velocity [m/s] in short and long-term postoperative period. | Measurements will be performed in routine visits in Transplant Centre. | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences in central aortic pressure [mmHg] in short and long-term postoperative period. | Measurements will be performed in routine visits in Transplant Centre. | 1 day | 
| Differences in central aortic pressure [mmHg] and cuff blood pressure [mmHg] in short and long-term postoperative period. | Measurements will be performed in routine visits in Transplant Centre. | 1 day |
CORONA in the Saarland

Study Overview
=================
Brief Summary
-----------------
The CORSAAR study is an observational, prospective study to investigate the natural biology of COVID-19

Detailed Description
-----------------
Patients with all forms of COVID-19 are included and followed up. Medical history, measurements and biomarkers are registered and collected at baseline, dung hospitalization and after discharge. In addition, patients with LONG-COVID-19 are recruited.

Official Title
-----------------
CORONA in the Saarland

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Diagnostic Test: Cytokine measurements


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all form of COVID-19 including long-COVID-19 Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 110 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Cytokine measurements|The serum concentrations of multiple cytokines are measured.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of biomarkers with mortality and disease subgroups |  | 2 years after initial disease |
Inter-Mountain Project on Antimicrobial Resistance and Therapy (IMPART)

Study Overview
=================
Brief Summary
-----------------
This is a four-year study, funded by the Center for Disease Control and Prevention, related to antimicrobial resistance in rural communities. The project consists of four components: A) surveillance of antimicrobial resistance, B) promotion of appropriate antimicrobial drug prescribing, C) preliminary assessment of the environmental impact of antimicrobials, and D) the development of new antimicrobial products. Six rural communities in Utah, and six rural communities in Idaho are participating in this study. Component D is being performed by investigators at Harvard University, under the direction of Co-Investigator Roger Inouye.

Official Title
-----------------
Inter-Mountain Project on Antimicrobial Resistance and Therapy (IMPART)

Conditions
-----------------
Upper Respiratory Infections

Intervention / Treatment
-----------------
* Device: Antimicrobial Prescribing Decision Support


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspected upper respiratory infection patients in 12 rural communities in Utah and Idaho Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Antimicrobial Prescribing Decision Support|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |